Am J Perinatol
DOI: 10.1055/s-0043-1776347
Original Article

Maternal and Neonatal Outcomes at Periviable Gestation throughout Delivery Admission

Angela R. Seasely
1   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
,
Victoria C. Jauk
2   Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
3   Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama
,
Jeff M. Szychowski
2   Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
3   Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama
,
4   Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama
,
Alan T. Tita
1   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
2   Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
,
Brian M. Casey
1   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
2   Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
› Author Affiliations
Funding None.

Abstract

Objective The threshold of viability, as well as cutoffs for delivery interventions and neonatal resuscitation, vary by hospital and involve complex counseling. With improvements in neonatal resuscitation and intensive care, the threshold of viability has been decreasing. Decisions regarding delivery planning and neonatal resuscitation efforts should be based on the best available evidence. Our objective was to characterize survival rates and neonatal outcomes following periviable birth at different milestones beginning with prenatal admission through 1 year of life in a contemporary cohort.

Study Design We performed a retrospective cohort study of all inborn infants without major congenital anomalies who delivered at the University of Alabama at Birmingham from 2013 to 2019 at gestational ages 22+0/7 to 25+6/7. Our primary outcome was to compared survival milestones throughout the pre- and postdelivery periods and neonatal complications in surviving newborns through 1 year of life at each gestational age.

Results The survival rate to 1 year of life was 49% (48–56%, 95% confidence interval [CI]) for the entire cohort and varied according to gestational age at delivery (22 weeks 15% [10–23%, 95% CI], 23 weeks 48% [43–58%, 95% CI], 24 weeks 57% [52–67%, 95% CI], 25 weeks 71% [67–82%, 95% CI]). Overall for the entire cohort, the rate of lung disease requiring respiratory support at discharge was 51%, intraventricular hemorrhage was 42%, retinopathy of prematurity was 74%, pulmonary hypertension was 30%, and concerns for cerebral palsy at 1 year of life was 25%. All outcomes improved with advancing gestational age at delivery. Of infants who delivered during the 22nd week of gestation, 50% received antenatal corticosteroids. Infants exposed to antenatal corticosteroids had more interventions, less pulmonary hypertension, and improved survival to 1 year of life.

Conclusion Knowledge of maternal complications, longitudinal survival rates, and neonatal outcomes of periviable deliveries according to gestational age throughout the admission enhances obstetric and perinatal counseling after hospital admission.

Key Points

  • Periviable birth outcomes at different delivery milestones is important for counseling.

  • Providing contemporary outcomes for periviable deliveries is critical for accurate counseling.

  • Administration of antenatal corticosteroids at 22 weeks' gestation appears beneficial overall.

Note

Abstract presented at the virtual 42nd Annual Pregnancy Meeting of the Society for Maternal Fetal Medicine (January 31 to February 5, 2022).




Publication History

Received: 14 September 2022

Accepted: 26 September 2023

Article published online:
01 November 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine. Obstetric care consensus no. 6: periviable birth. Obstet Gynecol 2017; 130 (04) e187-e199
  • 2 Kyser KL, Morriss Jr. FH, Bell EF, Klein JM, Dagle JM. Improving survival of extremely preterm infants born between 22 and 25 weeks of gestation. Obstet Gynecol 2012; 119 (04) 795-800
  • 3 Rysavy MA, Li L, Bell EF. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Between-hospital variation in treatment and outcomes in extremely preterm infants. N Engl J Med 2015; 372 (19) 1801-1811
  • 4 American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine in collaboration with Alison G, Cahill M, MSCI. Kaimal AJ, Kuller AJ, Turrentine MA. Use of antenatal corticosteroids at 22 weeks of gestation. Accessed August 08, 2021 at: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/09/use-of-antenatal-corticosteroids-at-22-weeks-of-gestation
  • 5 Committee opinion no 700: methods for estimating the due date. Obstet Gynecol 2017; 129 (05) e150-e154
  • 6 Grobman WA, Kavanaugh K, Moro T, DeRegnier RA, Savage T. Providing advice to parents for women at acutely high risk of periviable delivery. Obstet Gynecol 2010; 115 (05) 904-909
  • 7 Rossi RM, DeFranco EA. Maternal complications associated with periviable birth. Obstet Gynecol 2018; 132 (01) 107-114
  • 8 Carlo WA, McDonald SA, Fanaroff AA. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. JAMA 2011; 306 (21) 2348-2358
  • 9 Backes CH, Rivera BK, Pavlek L. et al. Proactive neonatal treatment at 22 weeks of gestation: a systematic review and meta-analysis. Am J Obstet Gynecol 2021; 224 (02) 158-174
  • 10 Ehret DEY, Edwards EM, Greenberg LT. et al. Association of antenatal steroid exposure with survival among infants receiving postnatal life support at 22 to 25 weeks' gestation. JAMA Netw Open 2018; 1 (06) e183235
  • 11 NICHD. Extremely preterm birth outcome tool. Accessed August 08, 2021 at: https://www.nichd.nih.gov/research/supported/EPBO/use